Expression and clinicopathological significance of miR-193a-3p and its potential target astrocyte elevated gene-1 in non-small lung cancer tissues

Table 1 The relationship between microRNA-193a and clinicopathological parameters in NSCLC

Clinicopathological feature	N	MiRNA-193a relevant expression (2^−ΔCq)
Clinicopathological feature	N	Mean ± SD	t	P value
Tissue
NSCLC	125	4.5076 ± 2.7700	−7.068	<0.001
Adjacent non-cancerous lung	125	7.0791 ± 2.9787
Age (years)
<60	57	4.3444 ± 2.4196	−0.602	0.549
≥60	68	4.6444 ± 3.0439
Gender
Male	75	4.3977 ± 2.6627	−0.542	0.589
Female	50	4.6724 ± 2.9433
Smoke
No	38	4.2087 ± 2.3248	0.461	0.646
Yes	30	3.9533 ± 2.1905
Tumor size (cm)
≤3	60	5.3203 ± 2.8395	3.273	0.001
>3	65	3.7574 ± 2.4984
Lymph node metastasis
No	56	5.0861 ± 2.8002	2.133	0.035
Yes	69	4.0381 ± 2.6739
Vascular invasion
No	90	4.3372 ± 2.6727	−1.104	0.272
Yes	35	4.9457 ± 3.0016
TNM
I–II	54	5.3269 ± 3.0154	2.885	0.005
III–IV	71	3.8845 ± 2.4074
Pathological grading
I	17	3.0353 ± 1.9371	F = 3.271^a	0.041
II	78	4.8827 ± 2.7938
III	30	4.3667 ± 2.8883
Histological classification
Adenocarcinoma	101	4.4685 ± 2.8159	0.276	0.759
Squamous carcinoma	23	4.5926 ± 2.6476
Large cell carcinoma	1	6.5000
EGFR amplification
No	39	4.4905 ± 2.2605	1.501	0.139
Yes	18	3.4889 ± 2.5128
EGFR protein expression
Low	40	4.6058 ± 2.4525	2.181	0.034
High	17	3.1588 ± 1.8426
EGFR mutation
Wild type	44	4.1030 ± 2.2729	−0.415	0.680
Mutation	13	4.4154 ± 2.7501

NSCLC non-small-cell lung cancer, N number, SD standard deviation, TNM tumor node metastasis, EGFR epidermal growth factor receptor.
Pathological grading I vs. II: P = 0.012, I vs. III: P = 0.110, II vs. III: P = 0.379.
^aANOVO test was performed.

ISSN: 1475-2867